A Phase 1 interventional study of Oxycodone and Oxycodone in Pain, sponsored by Pain Therapeutics. Completed at 1 site in Singapore. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-31.
Sponsored by Pain Therapeutics · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing oxycodone in Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Oxycodone · Pain.
Among the 50 studies testing oxycodone in Pain, this one is the 43rd largest by enrollment, is one of 6 that started in 2012, is one of 10 in phase 1, and was the 15th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →4 of the 50 studies testing oxycodone in Pain are open now, in 2 countries. Recruiting first, the newest first:
Kafrelsheikh University · Sites in Egypt
Ages 18–65
University of Florida · Sites in United States
Ages 45–85 · Healthy volunteers
University of Florida · Sites in United States
Ages 21–45 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 21 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 6 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 67 across the 50 interventional studies. Of the 37 that completed or were terminated, 13 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 50 have an industry lead sponsor. The 10 most frequent:
Pain Therapeutics is the lead sponsor of 16 studies on the registry; none are open to participants now.
Pain Therapeutics has 3 studies filed under Pain — fewer than ten, so there is no comparison to draw.
3 of the studies testing oxycodone in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05761860University of FloridaThe Potential of Oxytocin to Reduce Opioid Abuse Liability and Pain Among Older Adults | 2026-12 |
| NCT04218409University of FloridaOpioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination | 2026-12-31 |
| NCT05548582Johns Hopkins UniversityReduced Opioid Prescription After Laparoscopic Hysterectomy | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 50 studies testing oxycodone in Pain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To estimate the pharmacokinetics and relative bioavailability of oxycodone after administration of 40 mg doses of four PF-00345439 formulations and oxycodone in solution
This study will estimate the PK and relative bioavailability of oxycodone following single oral 40-mg doses of 3 modified PF-00345439 Formulations B, C, and D compared with the reference Formulation A under fed conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
Drug: Oxycodone
single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
Drug: Oxycodone
single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
Drug: Oxycodone
single dose of 40 mg PF-00345439 capsule under 50 mg naltrexone block
Drug: Oxycodone
40 mg oxycodone oral solution (5 mg/5 ml) under 50 mg naltrexone block
Drug: Oxycodone
1X40 mg PF-00345439 formulation A capsule with water and under fed condition
1X40 mg PF-00345439 formulation B capsule with water and under fed condition
1X40 mg PF-00345439 formulation C capsule with water and under fed condition
1X40 mg PF-00345439 formulation D capsule with water and under fed condition
40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) (if data permit, otherwise Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUClast]) of oxycodone.
Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
Maximum Observed Plasma Concentration (Cmax)
Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of oxycodone, as data permit.
Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) of oxycodone, as data permit.
Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
Plasma Decay Half-Life of oxycodone, as data permit.
Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
Concentration at time 24 hours (C24) of oxycodone, as data permit.
Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
Adverse events, vital signs and laboratory parameters.
Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, 48 hours post-dose
The record gives a start of Apr 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxycodone
Pain Therapeutics